SLNCF (Silence Therapeutics) Days Sales Outstanding : 2.54 (As of Dec. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Silence Therapeutics Days Sales Outstanding?

Silence Therapeutics's average Accounts Receivable for the three months ended in Dec. 2024 was $0.68 Mil. Silence Therapeutics's Revenue for the three months ended in Dec. 2024 was $24.33 Mil. Hence, Silence Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2024 was 2.54.

The historical rank and industry rank for Silence Therapeutics's Days Sales Outstanding or its related term are showing as below:

SLNCF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.32 Med: 198.47 Max: 16574.32
Current: 24.27

During the past 13 years, Silence Therapeutics's highest Days Sales Outstanding was 16574.32. The lowest was 5.32. And the median was 198.47.

SLNCF's Days Sales Outstanding is ranked better than
88.04% of 853 companies
in the Biotechnology industry
Industry Median: 72.85 vs SLNCF: 24.27

Silence Therapeutics's Days Sales Outstanding declined from Dec. 2023 (12.01) to Dec. 2024 (2.54).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Silence Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Silence Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Days Sales Outstanding Chart

Silence Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Sales Outstanding

Get a 7-Day Free Trial

976.27

439.87

13.10

8.06

5.32

Silence Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Sales Outstanding	Get a 7-Day Free Trial															12.01	30.78	748.89	75.16	2.54

Competitive Comparison of Silence Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Silence Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silence Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Days Sales Outstanding falls into.

Save Embed

;

Save Embed

;

Silence Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Silence Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

	Days Sales Outstanding (A: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (0.29	+	0.972)	/	2 )	/	43.258	*	365
=	0.631					/	43.258	*	365
=	5.32

Silence Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding (Q: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2024 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (0.385	+	0.972)	/	2 )	/	24.328	*	365 / 4
=	0.6785					/	24.328	*	365 / 4
=	2.54

Silence Therapeutics (OTCPK:SLNCF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Silence Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (OTCPK:SLNCF) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

SLN:USA XRP2:Germany XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.